Postmenopausal Vaginal Atrophy Market

Market Overview:

The 7 major postmenopausal vaginal atrophy markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 5.04% during 2024-2034.

The postmenopausal vaginal atrophy market has been comprehensively analyzed in IMARC's new report titled "Postmenopausal Vaginal Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Postmenopausal vaginal atrophy, also known as genitourinary syndrome of menopause, refers to a common condition that occurs in postmenopausal women due to decreased estrogen levels. Estrogen plays an important part in maintaining the health of vaginal tissues, and its decline after menopause can lead to the thinning, drying, and inflammation of the vaginal walls, resulting in illness. Women suffering from this ailment may experience a range of distressing symptoms, including vaginal dryness, itching, burning sensations, pain or discomfort during intercourse (dyspareunia), and increased susceptibility to vaginal infections. These indications can significantly impact the patient's quality of life, affecting their intimate relationships and overall well-being. The diagnosis of postmenopausal vaginal atrophy involves a comprehensive evaluation by a healthcare provider. The doctor will usually conduct a physical examination, review the patient's medical history, and check for specific symptoms. In some cases, a pelvic examination or vaginal swab may be performed to rule out various other potential causes of similar indications.

The increasing prevalence of menopause, in which the ovaries gradually produce less estrogen, leading to a significant decline in hormone levels, is primarily driving the postmenopausal vaginal atrophy market. In addition to this, the inflating utilization of effective hormone replacement therapy, including estrogen creams, tablets, and rings, as well as vaginal moisturizers and lubricants, is also creating a positive outlook for the market. These treatments aim to replenish estrogen levels in the vaginal tissues, thus alleviating the distressing symptoms and improving overall vulvovaginal health. Moreover, the widespread adoption of non-hormonal regimens, such as selective estrogen receptor modulators (SERMs) and tissue-selective estrogen complex (TSEC) medications, to treat moderate disease conditions by stimulating and stretching the vaginal muscles and reversing the narrowing of the vagina is further bolstering the market growth. Apart from this, the rising application of lifestyle changes and self-care practices, including regular sexual activity, pelvic floor exercises, and a balanced diet, since they help in mitigating the impact of the disorder on a patient's quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of novel treatment options like laser therapy and platelet-rich plasma injections, which target vaginal rejuvenation to improve tissue health and function, is expected to drive the postmenopausal vaginal atrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the postmenopausal vaginal atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for postmenopausal vaginal atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the postmenopausal vaginal atrophy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the postmenopausal vaginal atrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the postmenopausal vaginal atrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current postmenopausal vaginal atrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance 
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the postmenopausal vaginal atrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the postmenopausal vaginal atrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the postmenopausal vaginal atrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of postmenopausal vaginal atrophy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of postmenopausal vaginal atrophy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of postmenopausal vaginal atrophy by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of postmenopausal vaginal atrophy by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with postmenopausal vaginal atrophy across the seven major markets?
• What is the size of the postmenopausal vaginal atrophy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of postmenopausal vaginal atrophy?
• What will be the growth rate of patients across the seven major markets?
   

Postmenopausal Vaginal Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for postmenopausal vaginal atrophy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the postmenopausal vaginal atrophy market?
• What are the key regulatory events related to the postmenopausal vaginal atrophy market?
• What is the structure of clinical trial landscape by status related to the postmenopausal vaginal atrophy market?
• What is the structure of clinical trial landscape by phase related to the postmenopausal vaginal atrophy market?
• What is the structure of clinical trial landscape by route of administration related to the postmenopausal vaginal atrophy market?